MX343996B - Human antibodies that bind human tnfa. - Google Patents

Human antibodies that bind human tnfa.

Info

Publication number
MX343996B
MX343996B MX2013008395A MX13008395A MX343996B MX 343996 B MX343996 B MX 343996B MX 2013008395 A MX2013008395 A MX 2013008395A MX 13008395 A MX13008395 A MX 13008395A MX 343996 B MX343996 B MX 343996B
Authority
MX
Mexico
Prior art keywords
htnfalpha
antibodies
human antibodies
human
activity
Prior art date
Application number
MX2013008395A
Other languages
Spanish (es)
Inventor
G Salfeld Jochen
J Allen Deborah
Kaymakcalan Zehra
Labkovsky Boris
A Mankovich John
T Mcguiness Brian
J Roberts Andrew
Sakorafas Paul
R J M Hoogenboom Hendricus
Schoenhaut David
J Vaughan Tristan
White Michael
J Wilton Alison
Original Assignee
Abbvie Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/599,226 external-priority patent/US6090382A/en
Application filed by Abbvie Biotechnology Ltd filed Critical Abbvie Biotechnology Ltd
Publication of MX343996B publication Critical patent/MX343996B/en

Links

Landscapes

  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor alpha (hTNFalpha) are disclosed. These antibodies have high affinity for hTNFalpha (e.g., Kd=10-8 M or less), a slow off rate for hTNFalpha dissociation (e.g., Koff=10-3 sec-1 or less) and neutralize hTNFalpha activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFalpha and for inhibiting hTNFalpha activity, e.g., in a human subject suffering from a disorder in which hTNFalpha activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
MX2013008395A 1996-02-09 1998-08-06 Human antibodies that bind human tnfa. MX343996B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/599,226 US6090382A (en) 1996-02-09 1996-02-09 Human antibodies that bind human TNFα
US3147696P 1996-11-25 1996-11-25
US3147696A 1996-11-25 1996-11-25

Publications (1)

Publication Number Publication Date
MX343996B true MX343996B (en) 2016-12-02

Family

ID=58737874

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013008395A MX343996B (en) 1996-02-09 1998-08-06 Human antibodies that bind human tnfa.

Country Status (1)

Country Link
MX (1) MX343996B (en)

Similar Documents

Publication Publication Date Title
NO2017038I2 (en) Adalimumab - Extended SPC
CA2389943A1 (en) Human antibodies that bind human tnf.alpha.
TW200738749A (en) Human antibodies that bind human IL-12 and methods for producing
MXPA04001344A (en) Antagonistic anti-htnfsf13b human antibodies.
EP1490405A4 (en) ANTAGONISTIC ANTI-hFAS LIGAND HUMAN ANTIBODIES AND FRAGMENTS THEREOF
MX343996B (en) Human antibodies that bind human tnfa.